Retension Pharmaceuticals' IPO

Listed Oct 9, 2026 at $12 on Nasdaq as RTSN.

Offer price

$12

Market cap

$100M

3,750,000

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed Oct 9, 2026.

What does Retension Pharmaceuticals do?

“We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.”

From its final prospectus (424B4), filed Oct 9, 2026

Retension Pharmaceuticals' facts, each with its source
Fact	Retension Pharmaceuticals
Founded	2023From its final prospectus (424B4) of Oct 9, 2026
Headquarters	Falls Church, VirginiaFrom its final prospectus (424B4) of Oct 9, 2026
Website	retensionpharmaceuticals.comFrom its final prospectus (424B4) of Oct 9, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Retension Pharmaceuticals' facts, each with its source
Fact	Retension Pharmaceuticals
Shares offered	3,750,000From the final prospectus (424B4) filed Oct 9, 2026
Offer price	$12 a shareFrom the final prospectus (424B4) filed Oct 9, 2026
Raised at that price	$45 millionFrom the final prospectus (424B4) filed Oct 9, 2026
Underwriters' discount	$3.1 millionFrom the final prospectus (424B4) filed Oct 9, 2026
Underwriters' option	562,500 more sharesFrom the final prospectus (424B4) filed Oct 9, 2026
Underwriters	Leerink Partners, Guggenheim Securities, Oppenheimer, and Titan PartnersFrom the final prospectus (424B4) filed Oct 9, 2026, as its cover names them
Exchange	Nasdaq Capital Market, as RTSNFrom the final prospectus (424B4) filed Oct 9, 2026
Shares outstanding after	8,331,599From the final prospectus (424B4) filed Oct 9, 2026
Market cap at the offer price	$100 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Retension Pharmaceuticals' facts, each with its source
Fact	Retension Pharmaceuticals
Revenue	None from product sales yetFrom its final prospectus (424B4) of Oct 9, 2026: it has not generated any revenue
Net loss	$6.3 million, year to December 31, 2025From its final prospectus (424B4) of Oct 9, 2026, its summary financial data
Raised before the IPO	$31 million in private financingsFrom its final prospectus (424B4) of Oct 9, 2026

What risks does Retension Pharmaceuticals name first?

“We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.”
“Our recurring losses from operations and financial condition raise substantial doubt about our ability to continue as a going concern and the report of our independent registered public accounting firm on our financial statements as of and for the fiscal year ended December 31…”
“We will require substantial additional capital to finance our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Retension Pharmaceuticals' IPO

Retension Pharmaceuticals' IPO dates, each with its source
What	Day	Source
Registration filedForm S-1, SEC EDGAR	Sep 18, 2026	Form S-1, SEC EDGAR
Exchange registration filedexchange registration (Form 8-A), SEC EDGAR	Oct 8, 2026	exchange registration (Form 8-A), SEC EDGAR
Declared effective by the SECSEC notice of effectiveness, SEC EDGAR	Oct 8, 2026	SEC notice of effectiveness, SEC EDGAR
Pricedfinal prospectus (424B4), filed Oct 9, SEC EDGAR	Oct 8, 2026	final prospectus (424B4), filed Oct 9, SEC EDGAR
First tradeMassive's IPO calendar	Oct 9, 2026	Massive's IPO calendar
Lock-upNo SEC filer number on record for the ticker	Not read	No SEC filer number on record for the ticker

How did its first days trade?

From its daily bars, each close against its $12 offer price.

Retension Pharmaceuticals' first sessions
Day	Open	Close	From the offer
Oct 9	$10	$10.53	-12.3%
Oct 12	$10.88	$11.32	-5.7%
Oct 13	$11.83	$11.63	-3.1%
Oct 14	$11.63	$11.64	-3.0%
Oct 15	$11.56	$12.21	+1.8%

The other IPOs expected

The other IPOs expected or in registration
Company	Price	Market cap	Expected
OPAYNYSE: OPAY · No day yet	$19 to $21	Not yet	No day yetexchange registration Oct 26
Georgia BankingNasdaq: GBC · No day yet	Direct	Not yet	No day yetexchange registration Oct 21
Aspen NeuroscienceNasdaq: ASPE · No day yet	$15 to $17About $465M	$465Mat the midpoint	No day yetterms set Oct 26
Bambusa TherapeuticsNasdaq: BBTX · No day yet	$15 to $17About $796M	$796Mat the midpoint	No day yetterms set Oct 26
BitariNasdaq: BIAI · No day yet	$7About $302M	$302Mat the midpoint	No day yetterms set Oct 26
LIS TechnologiesNasdaq · No day yet	$5 to $7	Not yet	No day yetterms set Oct 26

Retension Pharmaceuticals IPO questions

When is Retension Pharmaceuticals' IPO?

Listed Oct 9, 2026 at $12 on Nasdaq as RTSN.

What is Retension Pharmaceuticals' IPO price?

Retension Pharmaceuticals' IPO priced at $12 a share, per its final prospectus of Oct 9, 2026.

How many shares is Retension Pharmaceuticals selling?

3,750,000 shares, and the underwriters may buy 562,500 more, per its final prospectus (424B4).

Who are the underwriters?

Leerink Partners, Guggenheim Securities, Oppenheimer, and Titan Partners, as the prospectus's cover names them.

Does Breakaway rate Retension Pharmaceuticals?

Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.

Can Breakaway say where Retension Pharmaceuticals' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and October 2026's listings.